Add to ORKGA 50-year-old male was diagnosed with chronic myelogenous leukaemia (CML) in chronic phase in March 2000. He was treated initially with hydroxyurea, administered orally. This was changed to interferon alpha (IFN) 5 million units (5 MIU) subcutaneously daily in May 2000; complete cytogenetic response was achieved 11 months later. IFN dosage was reduced to 5 MIU, alternate days, in June 2001 and a cytogenetic relapse occurred 3 months later. Since April 2002, he has received IFN 5 MIU three times weekly in combination with imatinib 200 mg/day. The Philadelphia chromosome disappeared from his peripheral blood cells in July 2002 and a complete molecular response was achieved in January 2003. Serial molecular studie
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remission...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard...
Imatinib has become the gold standard therapy for Ph(+) CML, as it induces complete cytogenetic remi...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Patients with chronic myeloid leukemia, treated with imatinib, who have a durable complete molecular...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remi...
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual diseaseHaem...
Imatinib (Gleevec®/Glivec®) has demonstrated high and durable hematologic and cytogenetic response r...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remission...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard...
Imatinib has become the gold standard therapy for Ph(+) CML, as it induces complete cytogenetic remi...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Patients with chronic myeloid leukemia, treated with imatinib, who have a durable complete molecular...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remi...
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual diseaseHaem...
Imatinib (Gleevec®/Glivec®) has demonstrated high and durable hematologic and cytogenetic response r...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remission...
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg dail...